Abiopharma

🔍 Japan Post Holdings Co., Ltd. (Executive)

Company: AFLAC INC (AFL)

Report Date: 2026-03-20

Detailed Transactions and Holdings:

• Sold 14,851 shares of Common Stock at $106.33 per share (Direct)
  Date: 2026-03-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 52,063,749.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,949 shares of Common Stock at $107.53 per share (Direct)
  Date: 2026-03-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 52,061,800.00 | transaction_form_type: 4 | Footnotes: F3, F2

Footnotes:

• F1: The price reported represents the weighted average price of shares of Common Stock of Aflac Inc. (the "Issuer") sold in multiple transactions at prices ranging from $106.14 to $107.07 per share. The reporting person will provide to the Issuer, or the Securities and Exchange Commission staff, upon request, information regarding the number of shares sold at each price within the range.
• F2: The reported securities are held directly by J&A Alliance Holdings Corporation ("J&A Holdings"), in its capacity as the trustee of the J&A Alliance Trust (the "Trust"). General Incorporated Association J&A Alliance ("General Incorporated") and Kenji Sano each may be deemed to beneficially own the securities held by J&A Holdings (in its capacity as trustee of the Trust) because (i) General Incorporated owns J&A Holdings and (ii) Kenji Sano owns 100% of the equity interests in General Incorporated. Japan Post Holdings Co., Ltd. ("Japan Post") may be deemed to beneficially own the shares of common stock owned directly by J&A Holdings, in its capacity as the trustee of the Trust, due to its role as the sole settlor and beneficiary of the Trust. Each of General Incorporated, Kenji Sano and Japan Post expressly disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
• F3: The price reported represents the weighted average price of shares of Common Stock of the Issuer sold in multiple transactions at prices ranging from $107.23 to $107.935 per share. The reporting person will provide to the Issuer, or the Securities and Exchange Commission staff, upon request, information regarding the number of shares sold at each price within the range.